Delving into the Latest Updates on Lais with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

LAIS, monomeric allergoid vaccine (Lofarma)

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System Diseases

Active Indication

Hypersensitivity

Inactive Indication-

Originator Organization

Lofarma SpA

Active Organization

Lofarma SpA

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Italy (17 May 2001),

Hypersensitivity

Regulation-

Login to view timeline

A prospective, multicenter, double-blind, placebo-controlled randomized study to assess efficacy and safety of LAIS® Grass pollen tablets in patients with seasonal grass pollen-induced allergic rhinoconjunctivitis - LAIS® Grass pollen tablets in seasonal grass pollen-induced allergic rhinoconjunctivitis

Start Date12 Sep 2019

Sponsor / Collaborator-

EUCTR2017-005079-21-DE

/ Not yet recruitingPhase 2

A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Allergic RhinoConjunctivitis Without or With Controlled Asthma using a Titrated Nasal Provocation Test model.

Start Date23 Aug 2018

Sponsor / Collaborator-

EUCTR2016-003439-39-DE

/ Unknown statusPhase 2

A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Allergic Rhino-Conjunctivitis Without or With Controlled Asthma in an Allergen Exposure Chamber (AEC)

Start Date22 May 2017

Sponsor / Collaborator-

100 Clinical Results associated with Lais

Login to view more data

100 Translational Medicine associated with Lais

Login to view more data

100 Patents (Medical) associated with Lais

Login to view more data

149

Literatures (Medical) associated with Lais

01 Apr 2025·Psychiatry Research

Latent variable analysis of adherence to antipsychotics among south carolina medicaid beneficiaries with schizophrenia or schizoaffective disorder

Article

Author: Benson, Carmela ; Patel, Charmi ; Cai, Chao ; Kozma, Chris ; Yunusa, Ismaeel ; Zhao, Pujing ; Reeder, Gene

Schizophrenia and schizoaffective disorder are chronic mental illnesses that may lead to positive symptoms, negative symptoms, or cognitive symptoms. This study examined latent classes within medication adherence profiles for long-acting injectable antipsychotics (LAIs) and oral antipsychotics (OAPs). Latent profile analysis (LPA) and multinomial logistic regression models were used to explore the association between patient characteristics and latent class membership. Four latent classes were identified using LPA with observed adherence measures. The classes were labeled as "best adherent", "intermittent adherent", "early drop-off", and "worst adherent", with their respective estimated prevalences of 58 %, 17 %, 9 %, and 16 %. Multinomial logistic regression showed that patients on LAIs were more likely to belong to the "best adherent" group than to the non-adherent groups ("intermittent adherent", "early drop-off", and "worst adherent") when compared to those on OAPs. These findings may contribute to the development of strategies for medication prescription and disease management for people with schizophrenia or schizoaffective disorder.

01 Mar 2025·Journal of Child and Adolescent Psychopharmacology

Long-Acting Injectable Antipsychotic Medication Use in Youth: A Systematic Review of the Literature Along with MedWatch Safety Data and Prescriber Attitudes

Review

Author: Sieracki, Rita ; Mireski, Sarah J. ; Scharko, Alexander M.

Objectives: Long-acting injectable (LAI) antipsychotic medications are being prescribed to children and adolescents along a broad age range from 2 to 17 years old. However, there is no U.S. Food and Drug Administration (FDA) approved indication for the use of any LAI in a pediatric population. The goal of this article is to perform a systematic literature review regarding the use of LAIs in a pediatric population, to obtain pediatric LAI safety data, and to survey prescriber attitudes regarding LAI use in youth. Methods: A search for relevant articles between June 1986 and June 2021 was conducted. Safety data were obtained from FDA MedWatch postmarketing adverse event reports regarding LAI use in children and adolescents. A survey of practicing Child and Adolescent Psychiatrists in Wisconsin was done regarding the use of LAIs in youth. Results: The predominant reasons for LAI use in youth were illness severity and treatment noncompliance. Twenty-six of 30 identified studies and reports favored LAI use in youth, but were of low to very low quality. Overall, 587 FDA MedWatch reports between June 1986 and June 2021 were identified. Most adverse events occurred in modest numbers. Extrapyramidal symptoms accounted for 18% of all MedWatch reports, neuroleptic malignant syndrome accounted for 3% of all reports, and deaths accounted for 2% of all reports. The concern for safety was reflected in prescriber survey results along with a recognition that LAIs can be helpful to target severe psychiatric symptoms and address treatment noncompliance. Conclusions: No randomized controlled studies were found. Identified published studies and reports were of low to very low quality. However, it appeared reasonable that the use of LAIs in a select group of pediatric patients can be helpful to target severe psychiatric symptoms and to enhance treatment compliance.

28 Feb 2025·Clinical Psychopharmacology and Neuroscience

Long-acting Injectable Aripiprazole (Abilify Maintena) Induced Rabbit Syndrome: A Case Report and Review of the Literature

Article

Author: Hsieh, Ming-Han ; Huang, Shang-Chien

Rabbit syndrome (RS), characterized by fine, rapid, rhythmic movements along the mouth's vertical axis, is typically linked to prolonged antipsychotic medication use. Emerging evidence suggests newer antipsychotics' involvement in RS, prompting investigation into its association with long-acting injectable antipsychotics (LAIs) for schizophrenia or bipolar disorder. We report a case of RS observed in a patient diagnosed with bipolar I disorder and treated with Abilify Maintena, highlighting the importance of vigilance in monitoring adverse effects. The patient, a 53-year-old male, experienced persistent manic episodes despite prior treatments. Upon initiation of Abilify Maintena 400 mg, RS symptoms manifested seven months later, remaining resistant to medication adjustments. This case emphasizes the significance of RS in LAIs-treated patients and emphasizes the need for further research into its mechanisms and optimal management strategies. Additionally, an updated review of RS associated with newer generation antipsychotics is provided to enhance understanding and clinical management.

100 Deals associated with Lais

Login to view more data